Home LifestyleHealth India responds to Indian officials’ vaccination “does not work”: two injections
More than 11,000 new cases have been confirmed in India, with a total of more than 10.7 million cases.

India responds to Indian officials’ vaccination “does not work”: two injections

by YCPress

According to the Times of India on the 5th, Anil Viji, Minister of Home Affairs and Health in Haryana, India, recently announced on Twitter that he had tested positive for COVID-19. He was vaccinated against Covaxin produced by Bharat Biotechnology Co, India, two weeks ago. Poison vaccine. Virgil’s test results raise doubts about the efficacy of the vaccine.

After learning that Virgil was still infected with the novel coronavirus after vaccination, the Indian government and vaccine developers quickly responded, saying that Virgil’s infection did not reflect the problem of the vaccine efficacy. India’s Ministry of Health and Family Welfare said antibodies against COVID-19 can only be produced within a specific time after the injection of a second shot. Balat also issued a statement on the 6th that the clinical trial of Covaxin vaccine is a course of treatment with two injections, with a interval of 28 days, and the effectiveness of the vaccine can only be determined 14 days after the injection of the second injection, while Vigi only gave the first injection, and was originally planned to inject the second injection on the 18th of this month.

At the same time, Barrat stressed that the vaccine trial took a randomized “double blind test”, that is, half of the volunteers were injected with the vaccine, while the other half were injected with placebos that did not have practical effect. Development companies, researchers and subjects did not know the specific grouping. The company has so far failed to say whether Viggie was injected with a vaccine or a placebo. According to the Indian news website Moneycontrol, if you want to find out whether Virjee was injected with a vaccine or a placebo, the whole trial needs to be blinded, but it is usually impossible to do so just for one subject.

Savita Vima, chief researcher of the Covaxin vaccine trial team in Haryana, while stressing that Vigi was not infected by the virus because of vaccination or placebo, cautiously said: “I want to appeal to all volunteers that there is always a risk of infection within 42 days after the first injection. ” Covaxin vaccine, developed by Bharat in conjunction with the Indian Medical Research Council, is currently vaccinated by nearly 26,000 volunteers in 25 pilots across the country. Virji is the first volunteer in the third phase of the Haryana vaccine human trial.